4 October 2022

Last updated: Monday 3 October 2022

Strategy

Microbiome-based therapies as anti-cancer agents

Antibody-drug conjugates come to the fore

Antimicrobial Review: New research, new payment models

Cancer Research UK has new model

How European MidPharmas have grown profits

Meeting the need for better reproductive health

A pioneer in RNA therapeutics maps out new strategy

Cell Therapy: TreeFrog Therapeutics on the go

Regulatory T cells to be tested in liver transplants

The next direction for Alzheimer's disease treatments